United States Drug Patent 4,322,438: Scope, Claims, Expiration, and Isotretinoin Patent Landscape

United States Patent No. 4,322,438 protected a specific oral isotretinoin treatment regimen for severe nodulocystic and conglobate acne. It did not claim isotretinoin itself, isotretinoin capsules, a formulation, or a manufacturing process. The patent required an initial high-dose period, a lower-dose continuation period, a 16-week treatment course, and patient selection based on inadequate early improvement.

The patent issued on March 30, 1982. Under the pre-1995 patent term applicable to the patent, its term expired on March 30, 1999. It therefore has no current blocking effect against generic isotretinoin, branded isotretinoin, or newer acne products. Its commercial importance is historical rather than current.

What does United States Patent 4,322,438 protect?

The patent protects a dose-escalation or dose-reduction regimen for oral administration of 13-cis-retinoic acid, now known as isotretinoin.

The independent claims require:

Claim element	Required limitation
Disease	Nodulocystic and conglobate acne in humans
Active ingredient	13-cis-retinoic acid, or isotretinoin
Route	Oral administration
Initial regimen	Approximately 1.0 to 2.0 mg/kg/day
Initial duration	Approximately 2 to 4 weeks
Patient selection	Patients whose acne has not substantially improved after the initial period
Response measure	Percentage reduction in cysts
Reduced regimen	Approximately 0.25 to 0.5 mg/kg/day
Reduced-dose duration	Approximately 12 to 14 weeks
Total course	Approximately 16 weeks

Claim 1 is the principal broad claim. Claim 6 is a narrower, fixed-dose version requiring 2.0 mg/kg/day for approximately four weeks, followed by 0.5 mg/kg/day for approximately 12 weeks.

The patent does not cover every isotretinoin treatment. A regimen that omits the initial high-dose period, uses a different treatment duration, treats a different acne population, or does not use the specified response-based dose reduction falls outside the literal scope of the independent claims.

How do the claims differ from one another?

Claim 1: variable dose and duration

Claim 1 allows:

1.0 to 2.0 mg/kg/day during the first period;
a first period of approximately two to four weeks;
0.25 to 0.5 mg/kg/day during the second period;
a second period of approximately 12 to 14 weeks;
a total treatment period of approximately 16 weeks.

The claim is conditional. The lower dose is administered to patients whose acne has not substantially improved at the end of the first period, measured by the percentage reduction in cysts.

That patient-selection limitation is central. A treatment protocol that automatically reduces the dose for every patient, without assessing inadequate improvement, may not literally practice the complete claim.

Claims 2 and 3: fixed initial duration

Claim 2 narrows claim 1 to an initial high-dose period of approximately two weeks.

Claim 3 narrows claim 1 to an initial high-dose period of approximately four weeks.

The claims retain the remaining requirements of claim 1, including the lower-dose period and the approximately 16-week total course.

Claims 4 and 5: lesion distribution and dose selection

Claim 4 applies where at least 60% of the patient's acne lesions appear on the face. It specifies:

approximately 1.0 mg/kg/day during the high-dose period; and
approximately 0.25 mg/kg/day during the low-dose period.

Claim 5 applies where at least 60% of the lesions appear on the trunk. It specifies:

approximately 2.0 mg/kg/day during the high-dose period; and
approximately 0.5 mg/kg/day during the low-dose period.

These claims create a facial-versus-truncal dosing distinction. They are narrower than claim 1 because they require a particular lesion distribution and fixed dose endpoints.

Claim 6: fixed high-dose and low-dose regimen

Claim 6 requires:

2.0 mg/kg/day for approximately four weeks;
reduction to 0.5 mg/kg/day for approximately 12 weeks;
use in patients who have not substantially improved after the first period; and
an approximately 16-week total treatment period.

Claim 6 is narrower than claim 1 but potentially easier to compare with a fixed clinical protocol because the dose and periods are specified.

Claims 7 and 8: repeat courses

Claim 7 covers repeating the regimen up to three times.

Claim 8 covers repeating the regimen upon each recurrence of acne.

These claims depend on the regimen in claim 1 or claim 6. They do not independently cover unrestricted repeated isotretinoin use. Each repeat must retain the limitations of the underlying regimen.

What is the patent expiration date?

The statutory expiration date was March 30, 1999.

Event	Date
Patent issued	March 30, 1982
Pre-1995 patent term	17 years from issuance
Expiration	March 30, 1999
Current enforceability	None

The patent was issued before the Uruguay Round Agreements Act changed U.S. patent term calculations to 20 years from the earliest effective filing date. For this patent, the applicable 17-year-from-issuance term controlled under the pre-1995 regime. The expired patent cannot support a new infringement action or prevent FDA approval of an isotretinoin product.

[U.S. Patent No. 4,322,438, 1982; 35 U.S.C. § 154.]

What is the Orange Book status of United States Patent 4,322,438?

United States Patent 4,322,438 has no operative Orange Book exclusivity value.

The Orange Book identifies patents and regulatory exclusivities associated with approved drug products. A patent that expired in 1999 cannot block approval or commercial launch of a current isotretinoin product, even if it appeared in historical patent records associated with an originator product.

Current isotretinoin products are subject to product-specific FDA records, labeling, and, where applicable, patent listings for later-developed formulations. Those later rights are separate from Patent 4,322,438 and cannot revive its expired claims.

The patent also did not claim:

isotretinoin as a chemical compound;
a capsule or soft-gel formulation;
a particular excipient system;
a food-effect or absorption profile;
a manufacturing process;
a controlled-release delivery system;
a pregnancy-prevention program; or
a later isotretinoin formulation such as a low-dose or micronized product.

Does Patent 4,322,438 create Paragraph IV risk today?

No. The patent is expired, so it cannot support a current Paragraph IV challenge or a 30-month stay under the Hatch-Waxman framework.

A Paragraph IV certification is relevant when an applicant challenges an unexpired listed patent. An applicant for a generic isotretinoin product does not need to certify that Patent 4,322,438 is invalid or not infringed as a current barrier. The patent's expiration removes it from the set of patents capable of delaying approval.

Historical ANDA litigation involving isotretinoin products may have included other patents, regulatory exclusivities, or product-specific formulation rights. Those matters do not extend the term of Patent 4,322,438.

What patent rights remain relevant to isotretinoin products?

The later isotretinoin landscape has focused on formulations, delivery systems, absorption characteristics, and product-specific regulatory rights rather than the original 16-week dose regimen.

Formulation patents

Later patents may address:

reduced dependence on administration with a high-fat meal;
micronized isotretinoin particles;
lipid-based or self-emulsifying delivery systems;
low-dose formulations;
improved bioavailability;
capsule composition;
stability and packaging; and
modified pharmacokinetic profiles.

These claims are materially different from Patent 4,322,438. A formulation patent may be infringed by making or selling a particular capsule even when the physician uses a different dosing schedule. Conversely, following the patented 16-week regimen does not by itself infringe a formulation claim.

Method-of-use patents

Later method claims may target:

specific acne subpopulations;
reduced-dose regimens;
relapse prevention;
treatment of disorders other than severe nodulocystic acne;
combination therapy; or
dosing based on cumulative exposure or pharmacokinetic response.

Patent 4,322,438 is unusually specific because it combines dose, duration, clinical response, lesion distribution, and recurrence-based retreatment.

Manufacturing and process patents

Process patents may cover synthesis, purification, crystallization, particle size, polymorph control, or encapsulation. Those rights can create manufacturing barriers even when the original treatment patent has expired.

They do not extend the expired monopoly over the regimen described in Patent 4,322,438.

How strong are the claims from a patent-scope perspective?

The patent was commercially meaningful when active, but its claim construction presents several limiting features.

Strengths of the claimed subject matter

The claims include multiple clinical variables that can distinguish the regimen from a general isotretinoin treatment:

severity and type of acne;
oral delivery;
initial high-dose therapy;
reduction to a lower dose;
a defined treatment window;
failure to improve after the initial period;
cyst-reduction measurement;
facial or truncal lesion distribution; and
repeated courses for recurrence.

Those limitations can make a literal infringement case more difficult against a regimen using continuous weight-based dosing, cumulative-dose targets, or physician discretion without the claimed response trigger.

Potential claim-construction pressure points

The principal interpretive issues would include:

The meaning of "about" for dose and treatment duration.
The meaning of "substantially improved."
The required method for measuring percentage reduction in cysts.
Whether dose reduction must occur only after inadequate improvement.
Whether a total course slightly longer or shorter than 16 weeks falls within the claims.
Whether a treatment protocol that permits, but does not require, the claimed dose reduction practices the claim.
The scope of "repeated upon each reoccurrence" in claim 8.

The claims are method claims, so infringement generally requires performance of the complete claimed treatment method. A manufacturer that sells isotretinoin may not directly perform the method merely by selling the drug. Induced-infringement exposure would require separate proof concerning knowledge and encouragement of the claimed method, but the patent's expiration makes that issue historical only.

What is the relationship between the patent and modern isotretinoin dosing?

Modern isotretinoin labeling generally uses individualized daily dosing, often within a range of approximately 0.5 to 1 mg/kg/day, with treatment adjusted according to response and adverse effects. Contemporary practice also considers cumulative exposure, laboratory monitoring, tolerability, and pregnancy-prevention requirements.

The claimed regimen is different because it starts with a high daily dose of 1.0 to 2.0 mg/kg/day and then reduces the dose for patients without substantial early improvement. It is not a claim to the commonly used isotretinoin dosing range as a whole.

Issue	Patent 4,322,438	Modern product practice
Core approach	High dose followed by lower dose	Individualized dosing
Initial dose	About 1.0 to 2.0 mg/kg/day	Often lower and adjusted clinically
Response trigger	Cyst reduction after 2 to 4 weeks	Clinical response and tolerability
Course	About 16 weeks	Variable
Repeat treatment	Up to three times or on recurrence	Based on recurrence and clinical judgment
Regulatory controls	No modern iPLEDGE framework in the patent	Pregnancy-prevention and risk-management requirements

FDA-approved isotretinoin products remain subject to prescribing restrictions and pregnancy-prevention controls under the iPLEDGE risk-management program. Those regulatory requirements are separate from the patent and do not create patent exclusivity. [U.S. Food and Drug Administration, 2024a; U.S. Food and Drug Administration, 2024b.]

Which companies challenged or replaced the original isotretinoin monopoly?

The original Accutane commercial franchise was associated with Hoffmann-La Roche. After the relevant patent term ended, multiple companies marketed generic isotretinoin products, including manufacturers and distributors of products such as Amnesteem, Claravis, and generic isotretinoin capsules.

Later branded products, including Absorica and Absorica LD, relied on distinct product formulations and regulatory strategies. Their commercial protection was not supplied by Patent 4,322,438.

The principal competitive categories are:

Category	Representative products	Protection focus
Originator	Accutane	Historical compound and regimen franchise
Conventional generics	Amnesteem, Claravis, generic isotretinoin	Abbreviated approval after patent and exclusivity barriers
Later branded products	Absorica, Absorica LD	Formulation, absorption, and product-specific rights
Competing acne therapies	Oral antibiotics, hormonal therapies, topical retinoids, biologics in other acne settings	Alternative treatment mechanisms

Because isotretinoin is a small molecule, biosimilar analysis does not apply. The relevant competitive pathway is generic substitution under the ANDA process, not the biosimilar pathway under the Public Health Service Act.

Are there licensing deals or settlement agreements tied to Patent 4,322,438?

No current license is required to practice or commercialize the regimen because the patent expired in 1999.

The patent itself does not establish a continuing royalty obligation. Any historical license, settlement, or supply agreement involving Roche or a generic manufacturer would have to be evaluated under its own contractual terms. Such a private agreement could affect historical launch timing or payment obligations, but it cannot restore patent enforceability after expiration.

No current commercial restriction attributable specifically to Patent 4,322,438 is apparent from the patent's expired status.

What litigation risk exists for generic isotretinoin?

Patent-specific litigation risk from Patent 4,322,438 is zero as a present matter because the patent is expired.

Historical litigation risk could have involved:

whether a generic label encouraged the patented regimen;
whether physicians selected patients using the claimed cyst-reduction criterion;
whether a generic manufacturer induced performance of the method;
whether the dose and duration fell within the "about" ranges;
whether later formulation patents covered the marketed capsule; and
whether FDA regulatory exclusivity delayed approval independently of patent term.

Current generic launch analysis must focus on later unexpired patents, product-specific Orange Book listings, pediatric exclusivity, formulation rights, and regulatory requirements. Patent 4,322,438 is not a current launch barrier.

What is the revenue exposure associated with the expired patent?

The patent had potential historical value because severe nodulocystic acne was a concentrated market for prescription isotretinoin, and the claims covered a defined treatment course rather than a narrow manufacturing step.

Current revenue exposure is zero from the patent itself:

it cannot prevent generic entry;
it cannot support a new injunction;
it cannot generate future patent royalties absent a separate surviving contract;
it cannot support a Paragraph IV stay; and
it cannot protect a current isotretinoin formulation.

Any present revenue protection for an isotretinoin product must come from a separate unexpired patent, regulatory exclusivity, brand differentiation, distribution controls, or formulation advantages.

How does Patent 4,322,438 compare with later isotretinoin patent estates?

Attribute	Patent 4,322,438	Later isotretinoin estates
Claim type	Method of treatment	Formulation, delivery, process, or later method
Active ingredient	Isotretinoin	Often isotretinoin, but claim scope varies
Main limitation	Dose sequence and clinical response	Product composition or pharmacokinetics
Patent status	Expired March 30, 1999	Must be assessed patent by patent
Current blocking value	None	Potentially significant if unexpired
Biosimilar relevance	None	None for small-molecule isotretinoin
Orange Book impact	Historical only	Product-specific
Generic risk	No risk from this patent	Depends on listed patents and certifications

Key Takeaways

Patent 4,322,438 covered a specific oral isotretinoin regimen, not isotretinoin generally.
The regimen required an initial high dose, a lower dose after inadequate early improvement, and an approximately 16-week course.
Claims 4 and 5 distinguished facial-predominant and truncal-predominant acne.
Claims 7 and 8 addressed repeated courses and recurrence.
The patent expired on March 30, 1999.
It has no current Orange Book blocking effect and cannot support a current Paragraph IV stay.
It did not claim formulations, manufacturing methods, capsules, pregnancy-prevention controls, or modern delivery systems.
Isotretinoin is a small molecule, so biosimilar risk is not the relevant framework.
Current competitive analysis must focus on later formulation, process, method-of-use, and product-specific patents.
No current license or settlement obligation follows from the expired patent alone.

FAQs About United States Patent 4,322,438

Can a generic manufacturer practice the dosing regimen in Patent 4,322,438 today?

Yes. The patent expired in 1999, so the regimen is no longer subject to patent enforcement.

Did Patent 4,322,438 cover Accutane itself?

No. It covered a method of administering oral 13-cis-retinoic acid for specified acne patients. It did not claim the isotretinoin molecule or all Accutane uses.

Does the patent cover low-dose isotretinoin treatment?

Not generally. The claims require an initial high-dose phase followed by a lower-dose phase and include additional disease, duration, and response limitations.

Does iPLEDGE extend the patent term?

No. iPLEDGE is an FDA risk-management program. It does not extend patent rights or create market exclusivity.

Could a later isotretinoin formulation still be patent-protected?

Yes. A later product may have separate patents covering formulation, absorption, particle size, excipients, manufacturing, or a distinct method of use. Those rights must be evaluated independently from Patent 4,322,438.

References

35 U.S.C. § 154. Patent term.
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: The Orange Book. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2024b). iPLEDGE risk evaluation and mitigation strategy. U.S. Department of Health and Human Services.
U.S. Patent No. 4,322,438. (1982). Method of treating acne with 13-cis-retinoic acid. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2024c). Isotretinoin prescribing information. U.S. Department of Health and Human Services.

Details for Patent: 4,322,438

Summary for Patent: 4,322,438